-
Sulfo-NHS-Biotin: From Chemistry to Assay Design
2026-09-15
Sulfo-NHS-Biotin is more than a membrane-impermeant labeling reagent: its reaction chemistry, spacer length, and capture format shape assay interpretation. This guide connects amine-reactive biotinylation with practical assay architecture and insights from a biotin-functionalized microsphere study.
-
AP-2α, MGMT, and TMZ Resistance in Recurrent GBM
2026-09-15
The reference study identifies AP-2α as a transcriptional suppressor of MGMT in recurrent glioblastoma and links this pathway to temozolomide sensitivity. By combining promoter-binding assays, DNA-damage measurements, cell models, and an intracranial relapsed-glioma model, the work connects transcriptional regulation with therapeutic response.
-
Hypoxia and Immunometabolism in the Tumor Microenvironment
2026-09-14
This Cancer Letters review presents hypoxia and immune-cell metabolism as mutually reinforcing processes that organize metabolic competition, immune dysfunction, and tumor progression. Its main contribution is an integrative framework for connecting oxygen limitation, nutrient use, immune phenotypes, and metabolism-directed therapeutic strategies.
-
PNU 74654 for Wnt Pathway Assays
2026-09-14
PNU 74654 provides a soluble-in-DMSO chemical tool for time-controlled Wnt/β-catenin pathway perturbation in cancer, stem cell, and differentiation assays. This guide translates the WNT5a/GSK3/β-catenin literature into practical workflows while separating evidence-based findings from assay-development recommendations.
-
PMSF in Epigenetic and Extracellular Vesicle Studies
2026-09-13
Discover how Phenylmethanesulfonyl fluoride (PMSF) can strengthen proteome-preservation strategies in shrimp hemocyte, epigenetic, and extracellular vesicle research. This guide connects selective serine protease inhibition with time-resolved assay design while defining PMSF’s important limitations.
-
10 mM dNTP Mixture for PCR and DNA Synthesis
2026-09-12
The 10 mM dNTP mixture is an equimolar aqueous PCR nucleotide mix containing dATP, dCTP, dGTP, and dTTP at 10 mM each. Its pH 7.0 formulation and storage guidance support reproducible DNA synthesis, while the cited LNP study defines a separate delivery context rather than evidence for dNTP-mediated intracellular transport.
-
Lactate as a Metabolic–Immune Control Point
2026-09-12
Lactate is moving from a passive glycolytic readout to a mechanistic control point in tumor–immune biology. This article translates the NAT1–ENO1–lactate–TRAF6–PD-L1 axis into practical experimental guidance for metabolic flux, hypoxia, mitochondrial, and immunotherapy research.
-
Hepatic sEH, Nrf2, and Osteoclastogenesis in Osteoporosis
2026-09-11
A recent Free Radical Biology and Medicine study identifies hepatic soluble epoxide hydrolase as an upstream regulator of osteoclastogenesis through circulating 14,15-EET, inflammatory cytokines, and Nrf2–ARE signaling. Its liver–bone axis model provides a mechanistic framework for studying redox imbalance in osteoporosis and for designing target-engagement experiments around epoxide lipid metabolism.
-
PDHA1 Succinylation and Immune Escape in Cholangiocarcinoma
2026-09-11
The reference study identifies PDHA1 lysine 83 succinylation as a metabolic-immune switch in cholangiocarcinoma. By increasing PDH activity and promoting alpha-ketoglutaric acid accumulation, this modification activates macrophage OXGR1–MAPK signaling, suppresses MHC-II antigen presentation, and contributes to chemotherapy resistance.
-
HyperScript III RT SuperMix for CRC Validation
2026-09-10
HyperScript III RT SuperMix can strengthen qPCR validation of colorectal cancer biomarkers by combining genomic DNA contamination removal with high-yield cDNA synthesis. This article translates bile acid metabolism subtyping into practical assay-design and interpretation decisions.
-
Entecavir (BMS200475) for HBV Research Workflows
2026-09-10
Entecavir (BMS200475) provides a nanomolar benchmark for concentration-response, genotype-aware, and chronic hepatitis B virus replication inhibition assays. This workflow guide shows how to handle BA1816, compare wild-type and lamivudine-resistant HBV models, and interpret resistance findings without confusing in vitro potency with clinical outcomes.
-
FLAG tag Peptide: Assay Design for Exosomes
2026-09-09
The FLAG tag Peptide and DYKDDDDK peptide enable controlled recombinant protein detection and affinity purification. This article develops a practical assay framework for applying competitive FLAG elution to mechanistic exosome studies while distinguishing established evidence from workflow recommendations.
-
BIBP 3226 Trifluoroacetate: NPY/NPFF Probe
2026-09-09
BIBP 3226 trifluoroacetate is a non-peptide antagonist for NPY Y1 and NPFF receptor studies. Its binding, cAMP, storage, and solubility data support controlled NPY/NPFF system research, while cardiovascular applications remain mechanistic rather than clinical.
-
Probenecid: From Mechanism to Translation
2026-09-08
A mechanism-first framework for using Probenecid to study transporter-mediated multidrug resistance, pannexin-1 biology, and neuroprotection while separating established evidence from translational hypotheses.
-
Improving In Vitro Metrics for Cancer Drug Responses
2026-09-08
Hannah R. Schwartz’s dissertation addresses a persistent problem in cancer pharmacology: relative viability and fractional viability are often treated as interchangeable even though they capture different aspects of drug response. By separating growth inhibition from cell killing and considering their timing, the work offers a more informative framework for interpreting in vitro drug-response experiments and designing follow-up studies.